Corpus Intelligence IC Memo — PAM SPEC HOSP OF HERITAGE VALLEY 2026-04-26 17:21 UTC
IC Memo — PAM SPEC HOSP OF HERITAGE VALLEY
Investment Committee Memorandum | PA | 35 beds | Grade D | EBITDA uplift $912K
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

PAM SPEC HOSP OF HERITAGE VALLEY

CCN 392043 | BEAVER, PA | 35 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

PAM SPEC HOSP OF HERITAGE VALLEY is a 35-bed community hospital in BEAVER, PA with $12.3M in net patient revenue and a 7.5% operating margin. The hospital serves a payer mix of 51.0% Medicare, 0.0% Medicaid, and 49.0% commercial.

Thesis: Turnaround. Our ML models identify $912K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 7.5% to 14.9% (+739bps).

Net Revenue HCRIS$12.3M
Current EBITDA COMPUTED$930K
Operating Margin COMPUTED7.5%
Occupancy HCRIS51.0%
Revenue / Bed COMPUTED$353K
Net-to-Gross HCRIS33.6%
Distress Probability MLnan%

2. Market Context & Competitive Position

225
PA Hospitals
-4.4%
State Median Margin
74
Comparable Hospitals

PA has 225 Medicare-certified hospitals with a median operating margin of -4.4%. The target's margin of 7.5% places it above the state median. Among 74 size-comparable peers (18-70 beds), the median margin is -0.1%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (18-70), prioritizing same-state peers. 74 hospitals in the comp set.

HospitalStateBedsRevenueMargin
PAM SPEC HOSP OF HERITAGE VALL (Target)PA35$12.3M7.5%
OSS ORTHOPAEDIC HOSPITALPA30$149.4M-5.0%
WELLSPAN SURGERY AND REHAB HOSPA25$120.2M2.8%
UPMC LITITZPA36$114.5M14.2%
MINERS MEMORIAL MEDICAL CENTERPA49$107.7M12.4%
LVH-COORDINATED ALLENTOWNPA20$89.6M2.3%
CHARLES COLE MEMORIAL HOSPITALPA25$88.1M-9.0%
ST LUKES HOSPITAL-CARBON CAMPUPA52$86.4M8.1%
POCONO MEDICAL CENTER DICKSON PA40$85.9M0.1%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $912K (739bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$259K+210bp18mo
Cost to Collect4.5%2.5%$247K+200bp12mo
Denial Rate Reduction12.0%6.5%$246K+199bp12mo
A/R Days Reduction5200.0%3800.0%$150K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+8bp6mo

5. EBITDA Bridge

Net Collection Rate
$259K
Cost to Collect
$247K
Denial Rate Reduction
$246K
A/R Days Reduction
$150K
Clean Claim Rate
$10K
Total EBITDA Uplift$912K
Current EBITDA$930K
+ RCM Uplift+$912K
Pro Forma EBITDA$1.8M
Current Margin7.5%
Pro Forma Margin14.9%
WC Released (1x)$474K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$1.4M$15.3M10.66x60.5%
Base (11x exit)10.0x11.0x$1.4M$17.2M12.06x64.5%
Bull Case9.0x11.0x$1.3M$20.7M16.09x74.3%
Bull (12x exit)9.0x12.0x$1.3M$23.0M17.85x78.0%
Bear Case11.0x10.0x$1.6M$10.2M6.50x45.4%
Bear (11x exit)11.0x11.0x$1.6M$11.8M7.48x49.5%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumStandard execution riskRCM improvement requires management buy-in and 12-18 month implementation timeline

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 74 hospitals with 18-70 beds
  • Same-state prioritization (n=75)
  • Comp margins: P25=-15.4% / P50=-0.1% / P75=8.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.